Sign in
Knowstox

Fundamentals snapshot

Ovid Therapeutics Inc.

OVID · NCM · Healthcare · Biotechnology

Current price

$2.54

52-week range

$1.18 - $3.10

Market cap

$496.06M

One-glance verdict

Undervalued

$15.48 our estimate vs market $2.54

Wall Street consensus: $6.40 (-58.6% lower than our fair-value estimate)

Balance sheet

Healthy

-10.88x Concerning

Net cash $104.50M. Interest coverage shows how many times profit covers the interest bill.

What this company does

Ovid Therapeutics Inc.

Ovid Therapeutics is a company working on new medicines for brain conditions like epilepsy and psychosis linked to Parkinson's disease. Their money comes from developing these potential new drugs and from partnerships with bigger pharmaceutical companies. This matters because if their drugs are successful, they could help many patients and generate significant revenue.

Price history

How the share price has moved

—
Loading price history…

Earnings history

Last 8 quarters — what happened

Click any quarter to read the call summary and what the numbers say.

Free cash flow by quarter (oldest to newest)
FY2024 Q3 $-15.01M FY2024 Q4 $-10.03M FY2025 Q1 $-10.28M FY2025 Q2 $-4.77M FY2025 Q3 $-12.87M FY2025 Q4 $-10.41M
Revenue $733.00K
Net income $-15.01M
Diluted EPS —
Operating cash flow $-17.59M
Free cash flow —
Revenue $0.00
Net income $-16.99M
Diluted EPS —
Operating cash flow $-13.90M
Free cash flow —
Revenue $718.00K
Net income $9.66M
Diluted EPS —
Operating cash flow $-10.41M
Free cash flow $-10.41M
Revenue $132.00K
Net income $-12.16M
Diluted EPS —
Operating cash flow $-12.87M
Free cash flow $-12.87M
Revenue $6.27M
Net income $-4.68M
Diluted EPS —
Operating cash flow $-4.77M
Free cash flow $-4.77M
Revenue $130.00K
Net income $-10.23M
Diluted EPS —
Operating cash flow $-10.28M
Free cash flow $-10.28M
Revenue $76.00K
Net income $-9.25M
Diluted EPS —
Operating cash flow $-10.01M
Free cash flow $-10.03M
Revenue $173.00K
Net income $-14.01M
Diluted EPS -0.20
Operating cash flow $-15.01M
Free cash flow $-15.01M

Is it cheap or expensive?

Fair value $15.48 vs current price $2.54

Wall Street consensus is the average analyst price target: $6.40 (-58.6% lower than our fair-value estimate).

Our most-likely fair value is $15.48 a share — about 509.3% above today's price of $2.54, so the stock currently looks cheap (undervalued).

undervalued

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Base

Growth 3.0% · Discount 7.2% · Terminal 3.0%

$15.48

Bear

Growth 3.0% · Discount 7.2% · Terminal 3.0%

$15.48

Bull

Growth 6.0% · Discount 7.2% · Terminal 3.0%

$18.41

Is it drowning in debt?

Healthy

Net cash $104.5M - more cash than debt. Interest coverage -10.9x.

Net debt $-104.50M
Interest coverage -10.88x

Ovid Therapeutics Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.

Healthy
Worse cushion Baseline Better cushion
OVID BASELINE Ovid Therapeutics Inc.

Total debt $12.71M Interest coverage -10.88x This is the baseline the peer rows are being compared against.

-10.88x
MPLT MapLight Therapeutics, Inc.

Total debt $1.99M Interest coverage -30.64x Neither company has much profit cushion over interest right now.

-30.64x
ENTX Entera Bio Ltd.

Total debt $425.00K Interest coverage -397.55x Neither company has much profit cushion over interest right now.

-397.55x
ALLO Allogene Therapeutics, Inc.

Total debt $79.01M Interest coverage -192.50x Neither company has much profit cushion over interest right now.

-192.50x
ALT Altimmune, Inc.

Total debt $36.02M Interest coverage -57.76x Neither company has much profit cushion over interest right now.

-57.76x

What you should know

The case for and against OVID

1 Reward 2 Risks

Rewards

  • Free cash flow was positive in 1/10 years.

Risks

  • Return on equity was -26.0% last year — the company lost money on shareholders' equity.
  • Insider ownership is only 6.7% (peer median: 8.2%).

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
—
Forward P/E
-6.93x
P/B
2.24x
P/S
313.36x
EV/EBITDA
-6.75x
PEG ratio
—

Profitability

How much profit each dollar creates

Gross margin
100.0%
Operating margin
-2,100.7%
Net margin
0.0%
ROE
-26.0%
ROA
-23.5%

Health

Liquidity and balance-sheet strength

Debt / equity
0.06x
Current ratio
12.39x
Quick ratio
11.74x
Total debt
$12.71M
Total cash
$117.22M

Growth

How the business has been compounding

Revenue TTM
$1.58M
Revenue 5Y CAGR
-68.1%
EPS TTM
-0.22
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$-54.77M
Free CF TTM
$-38.33M
FCF margin
-2,421.6%

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—